Zacks: Brokerages Expect Ocular Therapeutix Inc (NASDAQ:OCUL) to Post -$0.43 EPS

Brokerages predict that Ocular Therapeutix Inc (NASDAQ:OCUL) will report ($0.43) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Ocular Therapeutix’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.47). Ocular Therapeutix reported earnings per share of ($0.42) in the same quarter last year, which would suggest a negative year-over-year growth rate of 2.4%. The firm is scheduled to announce its next earnings report on Thursday, March 5th.

On average, analysts expect that Ocular Therapeutix will report full-year earnings of ($1.72) per share for the current financial year, with EPS estimates ranging from ($1.84) to ($1.60). For the next year, analysts forecast that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.50) to ($0.75). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The business had revenue of $0.83 million for the quarter, compared to analyst estimates of $1.09 million. Ocular Therapeutix had a negative net margin of 3,141.58% and a negative return on equity of 383.58%.

A number of equities analysts recently weighed in on OCUL shares. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Friday. JMP Securities reduced their target price on shares of Ocular Therapeutix from $9.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (down previously from $9.00) on shares of Ocular Therapeutix in a research note on Friday. Piper Jaffray Companies reduced their price target on shares of Ocular Therapeutix from $8.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. Finally, ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Ocular Therapeutix has a consensus rating of “Buy” and a consensus price target of $8.33.

Several hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Ocular Therapeutix during the third quarter worth about $32,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Ocular Therapeutix in the third quarter valued at approximately $38,000. Creative Planning boosted its holdings in shares of Ocular Therapeutix by 37.8% in the third quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,500 shares during the period. Highland Capital Management LLC acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at approximately $62,000. Finally, Sio Capital Management LLC acquired a new stake in shares of Ocular Therapeutix during the second quarter worth $263,000. 49.38% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ OCUL traded up $0.13 during midday trading on Friday, hitting $2.80. The stock had a trading volume of 700,600 shares, compared to its average volume of 376,995. The business’s 50 day moving average is $3.21 and its 200-day moving average is $3.91. The company has a quick ratio of 6.39, a current ratio of 6.33 and a debt-to-equity ratio of 5.07. The company has a market cap of $128.37 million, a P/E ratio of -1.78 and a beta of 2.13. Ocular Therapeutix has a 52 week low of $2.35 and a 52 week high of $6.88.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Featured Story: What is the LIBOR?

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.